A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
Phase
3Span
110 weeksSponsor
Eli Lilly and CompanyTampico, Tamaulipas
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.
Phase
2Span
321 weeksSponsor
Novartis PharmaceuticalsTampico, Tamaulipas
Recruiting
1-2 of 2